The pharmaceutical sector in Belgium and Europe reached a historical tipping point, navigating a landscape defined by rapid technological shifts, intensifying global competition and complex regulatory changes. As the industry stood at this crossroads, the fundamental questions regarding its long-term viability and strategic direction had never been more urgent. To address these challenges head-on, Itinera organised a high-level roundtable.

This session was designed to move well beyond standard industry rhetoric, providing instead a candid mapping of the new reality and the difficult choices ahead for policymakers, industry leaders and society at large.

As an independent think tank, Itinera recognized that the future of healthcare excellence and economic resilience depended entirely on how effectively we navigated this transition. Belgium had long served as a vital pharmaceutical hub, but its continued success was not guaranteed in an evolving global market. The discussion focused specifically on the strategic positioning of this Belgian hub within the broader European context, asking the necessary questions required to ensure the region remained a preeminent leader in global innovation. By analyzing the trajectory of the industry, the roundtable aimed to identify the pivotal decisions and structural reforms necessary to maintain a sustainable, competitive and patient-centric ecosystem. 

The complexity of that pharmaceutical environment required more than just incremental changes; it demanded a clear-eyed look at the structural shifts occurring in R&D, manufacturing and market access. Itinera’s role in this process was to facilitate a space where expertise met action. By bringing together deep industry knowledge and policy foresight, this initiative sought to define a trajectory that secured the sector's vital contribution to our economy and our health for decades to come. 

This important session took place on Monday, March 2nd, The Merode in Brussels. The proceedings were scheduled to run from 2 p.m. until 6 p.m., offering an afternoon of high-level debate and strategic insight. Through this initiative, Itinera continued its long-standing commitment to fostering the informed, evidence-based debate needed to shape a prosperous and innovative future for both Belgium and Europe.

This event was realized with the valued contribution of AstraZeneca and Novartis.